Pharmaceutical Preparations Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Pharmaceutical Preparations
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2019-01-14 | BMRN | Biomarin Pharmaceutical Inc | Bienaime Jean Jacques | CEO | S - Sale+OE | $93.79 | -4,000 | 469,791 | -1% | -$375,160 | |||||
2019-01-14 | ENDV | Endonovo Therapeutics, Inc. | Collier Alan Brian | CEO | P - Purchase | $0.03 | +45,000 | 20,646,123 | 0% | +$1,487 | ||||||
| M | 2019-01-11 | VRCA | Verrica Pharmaceuticals Inc. | Davidson Matt | 10% | S - Sale | $10.53 | -8,019 | 3,024,872 | 0% | -$84,472 | |||||
| M | 2019-01-09 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres | P - Purchase | $0.02 | +21,000 | 26,689,897 | 0% | +$498 | |||||
| D | 2019-01-11 | DCPH | Deciphera Pharmaceuticals, Inc. | Flynn Daniel Lee | Chief Scientific Officer | S - Sale+OE | $26.00 | -300 | 147,049 | 0% | -$7,800 | |||||
| DM | 2019-01-14 | UTHR | United Therapeutics Corp | Rothblatt Martine A | COB, CEO | S - Sale+OE | $114.85 | -14,108 | 683,795 | -2% | -$1,620,256 | |||||
2019-01-11 | XERS | Xeris Pharmaceuticals Inc | Prestrelski Steven | Chief Scientific Officer | S - Sale | $0.00 | -2,300 | 487,024 | 0% | -$0 | ||||||
| D | 2019-01-14 | VRTX | Vertex Pharmaceuticals Inc / Ma | Parini Michael | EVP, CL, AO | S - Sale+OE | $186.71 | -2,125 | 39,609 | -5% | -$396,759 | |||||
2019-01-14 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $3.74 | +15,000 | 212,304,633 | 0% | +$56,055 | ||||||
| D | 2019-01-10 | CCXI | Chemocentryx, Inc. | Schall Thomas J. | Pres, CEO | S - Sale+OE | $12.16 | -36,762 | 2,228,855 | -2% | -$447,092 | |||||
| D | 2019-01-10 | CCXI | Chemocentryx, Inc. | Cappel Markus J. | Chief Bus. Officer, Treasurer | S - Sale+OE | $12.00 | -6,172 | 35,441 | -15% | -$74,079 | |||||
| D | 2019-01-10 | BHVN | Biohaven Pharmaceutical Holding Co Ltd. | Tilton John | Chief Commercial Officer | S - Sale+OE | $37.67 | -10,500 | 1,614 | -87% | -$395,535 | |||||
2019-01-10 | INSM | Insmed Inc | Altomari Alfred | Dir | S - Sale | $22.50 | -5,500 | 42,442 | -11% | -$123,750 | ||||||
| AM | 2015-06-15 | ENDV | Endonovo Therapeutics, Inc. | Collier Alan Brian | CEO | P - Purchase | $0.00 | +20,601,123 | 39,827,780 | +107% | +$852 | |||||
| M | 2016-06-20 | ENDV | Endonovo Therapeutics, Inc. | Collier Alan Brian | CEO | P - Purchase | $0.00 | +1,045,000 | 20,271,657 | +5% | +$852 | |||||
2019-01-10 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres, COB, CEO, 10% | P - Purchase | $0.27 | +1,000 | 6,600,360 | 0% | +$270 | ||||||
2019-01-10 | SCYX | Scynexis Inc | Taglietti Marco | CEO | P - Purchase | $0.69 | +25,000 | 480,000 | +5% | +$17,250 | ||||||
| D | 2019-01-11 | UTHR | United Therapeutics Corp | Rothblatt Martine A | COB, CEO | S - Sale+OE | $113.59 | -7,054 | 683,795 | -1% | -$801,235 | |||||
2019-01-11 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $3.83 | +10,000 | 212,289,633 | 0% | +$38,325 | ||||||
2019-01-08 | STML | Stemline Therapeutics Inc | Hoberman Kenneth | COO | S - Sale | $10.15 | -13,547 | 646,652 | -2% | -$137,502 | ||||||
| D | 2019-01-10 | AMRN | Amarin Corp Plcuk | Zakrzewski Joseph S | Dir | S - Sale+OE | $16.98 | -200,000 | 84,547 | -70% | -$3,396,390 | |||||
2019-01-07 | MYOK | Myokardia Inc | Gianakakos Anastasios | Pres, CEO | S - Sale | $44.11 | -2,770 | 702,040 | 0% | -$122,197 | ||||||
| D | 2019-01-10 | AMRN | Amarin Corp Plcuk | Stack David M | Dir | S - Sale+OE | $18.00 | -125,504 | 0 | -100% | -$2,259,072 | |||||
| D | 2019-01-11 | AMRN | Amarin Corp Plcuk | Kennedy Joseph T | GC | S - Sale+OE | $18.92 | -3,173 | 217,934 | -1% | -$60,033 | |||||
| D | 2019-01-09 | AMRN | Amarin Corp Plcuk | Kalb Michael Wayne | SVP, CFO | S - Sale+OE | $15.26 | -200,000 | 17,486 | -92% | -$3,051,080 | |||||
| D | 2019-01-10 | AMRN | Amarin Corp Plcuk | Ekman Lars | Dir | S - Sale+OE | $17.28 | -140,416 | 0 | -100% | -$2,426,489 | |||||
2019-01-09 | FTSV | Forty Seven, Inc. | Weissman Irving | Dir | S - Sale | $17.05 | -10,000 | 2,132,761 | 0% | -$170,490 | ||||||
2018-12-26 | FTSV | Forty Seven, Inc. | Weissman Irving | Dir | S - Sale | $15.77 | -10,000 | 2,142,761 | 0% | -$157,685 | ||||||
2019-01-10 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale | $7.31 | -1,500 | 85,567 | -2% | -$10,965 | ||||||
2019-01-11 | SPPI | Spectrum Pharmaceuticals Inc | Turgeon Joseph W. | CEO, Pres | S - Sale | $10.87 | -36,311 | 413,632 | -8% | -$394,810 | ||||||
2019-01-11 | SPPI | Spectrum Pharmaceuticals Inc | Gustafson Kurt A | EVP, CFO | S - Sale | $10.87 | -33,692 | 227,056 | -13% | -$366,333 | ||||||
2019-01-11 | ARWR | Arrowhead Pharmaceuticals, Inc. | Waddill William D. | Dir | S - Sale | $14.77 | -8,500 | 46,500 | -15% | -$125,545 | ||||||
| M | 2019-01-09 | CERC | Cerecor Inc. | Armistice Capital, LLC | Dir, 10% | P - Purchase | $3.88 | +13,996 | 18,169,799 | 0% | +$54,335 | |||||
| D | 2019-01-10 | ENOB | Enochian Biosciences Inc | Gronfeldt-Sorensen Henrik | Dir | P - Purchase | $2.00 | +50,000 | 50,000 | New | +$100,000 | |||||
| D | 2019-01-09 | ACAD | Acadia Pharmaceuticals Inc | Brege Laura | Dir | S - Sale+OE | $20.00 | -10,000 | 0 | -100% | -$200,041 | |||||
| D | 2019-01-10 | ZGNX | Zogenix, Inc. | Farr Stephen J | Pres, CEO | S - Sale+OE | $45.00 | -90,313 | 51,947 | -63% | -$4,064,085 | |||||
| D | 2019-01-10 | REGN | Regeneron Pharmaceuticals Inc | Goldstein Joseph L | Dir | S - Sale+OE | $410.00 | -1,791 | 12,323 | -13% | -$734,310 | |||||
| D | 2019-01-10 | BMRN | Biomarin Pharmaceutical Inc | Bienaime Jean Jacques | CEO | S - Sale+OE | $90.55 | -3,000 | 469,791 | -1% | -$271,650 | |||||
2019-01-10 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $3.69 | +10,000 | 212,279,633 | 0% | +$36,908 | ||||||
| DM | 2019-01-08 | PAHC | Phibro Animal Health Corp | Bendheim Daniel M | EVP, Corporate Strategy | S - Sale+OE | $32.42 | -5,000 | 0 | -100% | -$162,125 | |||||
| M | 2019-01-08 | ARPO | Aerpio Pharmaceuticals, Inc. | Satter Muneer A | Dir, 10% | P - Purchase | $2.35 | +63,818 | 5,621,835 | +1% | +$150,290 | |||||
| D | 2019-01-08 | BMRN | Biomarin Pharmaceutical Inc | Bienaime Jean Jacques | CEO | S - Sale+OE | $91.59 | -6,000 | 469,791 | -1% | -$549,523 | |||||
2018-12-17 | KURA | Kura Oncology, Inc. | Ecor1 Capital Fund Qualified, L.P. | 10% | S - Sale | $13.20 | -26,520 | 4,408,097 | -1% | -$350,064 | ||||||
| M | 2018-12-18 | KURA | Kura Oncology, Inc. | Ecor1 Capital Fund Qualified, L.P. | 10% | P - Purchase | $13.57 | +213,888 | 4,408,097 | +5% | +$2,901,833 | |||||
2019-01-08 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres, COB, CEO, 10% | P - Purchase | $0.27 | +4,000 | 6,599,360 | 0% | +$1,070 | ||||||
| M | 2019-01-08 | VRCA | Verrica Pharmaceuticals Inc. | Davidson Matt | 10% | S - Sale | $10.87 | -15,802 | 3,032,891 | -1% | -$171,827 | |||||
2019-01-08 | TTPH | Tetraphase Pharmaceuticals Inc | Dumas Jacques | Chief ScientificOfficer | S - Sale | $1.60 | -7,497 | 0 | -100% | -$11,995 | ||||||
| DM | 2019-01-09 | UTHR | United Therapeutics Corp | Rothblatt Martine A | COB, CEO | S - Sale+OE | $113.51 | -14,108 | 683,795 | -2% | -$1,601,356 | |||||
2019-01-09 | FLKS | Flex Pharma, Inc. | Boston Foundation, Inc. | 10% | S - Sale | $0.37 | -337,000 | 1,600,000 | -17% | -$123,848 | ||||||
2019-01-09 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $3.65 | +10,000 | 212,269,633 | 0% | +$36,501 | ||||||
| M | 2019-01-07 | MRTX | Mirati Therapeutics, Inc. | Davis Aaron I. | Dir, 10% | S - Sale | $47.68 | -50,000 | 2,116,242 | -2% | -$2,383,803 | |||||
| DM | 2019-01-08 | MRTX | Mirati Therapeutics, Inc. | Boxer Capital, LLC | 10% | S - Sale+OE | $51.98 | -700,000 | 1,565,560 | -31% | -$36,389,172 | |||||
| DM | 2019-01-07 | CCXI | Chemocentryx, Inc. | Schall Thomas J. | Pres, CEO | S - Sale+OE | $12.02 | -20,170 | 2,228,855 | -1% | -$242,370 | |||||
2019-01-07 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres, COB, CEO, 10% | P - Purchase | $0.27 | +3,000 | 6,595,360 | 0% | +$810 | ||||||
2019-01-07 | ICPT | Intercept Pharmaceuticals, Inc. | Bright Lisa | Pres, International | S - Sale | $104.93 | -1,313 | 18,807 | -7% | -$137,773 | ||||||
| DM | 2019-01-07 | CCXI | Chemocentryx, Inc. | Cappel Markus J. | Chief Bus. Officer, Treasurer | S - Sale+OE | $12.03 | -13,203 | 35,441 | -27% | -$158,790 | |||||
| M | 2019-01-08 | RTRX | Retrophin, Inc. | Reed Elizabeth E | SVP, GC, Corporate Secretary | S - Sale | $23.95 | -1,500 | 16,327 | -8% | -$35,933 | |||||
| D | 2019-01-07 | FGEN | Fibrogen Inc | Schoeneck James A | Dir | S - Sale+OE | $45.90 | -2,000 | 27,700 | -7% | -$91,800 | |||||
2019-01-07 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | Chief Technical Ops Officer | S - Sale | $34.75 | -653 | 23,045 | -3% | -$22,692 | ||||||
2019-01-07 | PTCT | Ptc Therapeutics, Inc. | Souza Marcio | COO | S - Sale | $34.75 | -83 | 2,742 | -3% | -$2,884 | ||||||
2019-01-07 | PTCT | Ptc Therapeutics, Inc. | Utter Christine Marie | Principal Financial Officer | S - Sale | $34.75 | -297 | 7,446 | -4% | -$10,321 | ||||||
| D | 2019-01-07 | PTCT | Ptc Therapeutics, Inc. | Peltz Stuart Walter | CEO | S - Sale+OE | $34.75 | -2,512 | 42,420 | -6% | -$87,292 | |||||
| D | 2019-01-07 | DCPH | Deciphera Pharmaceuticals, Inc. | Kelly Thomas Patrick | CFO | S - Sale+OE | $25.18 | -5,000 | 0 | -100% | -$125,900 | |||||
| D | 2019-01-07 | RETA | Reata Pharmaceuticals Inc | Wilson Jason Douglas | CFO | S - Sale+OE | $72.04 | -20,000 | 0 | -100% | -$1,440,820 | |||||
| D | 2019-01-07 | KPTI | Karyopharm Therapeutics Inc. | Kauffman Michael | CEO | S - Sale+OE | $10.23 | -12,500 | 1,320,271 | -1% | -$127,824 | |||||
| D | 2019-01-07 | KPTI | Karyopharm Therapeutics Inc. | Shacham Sharon | Pres, CSO | S - Sale+OE | $10.23 | -12,500 | 1,320,271 | -1% | -$127,824 | |||||
| M | 2019-01-03 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres | P - Purchase | $0.02 | +8,200 | 26,668,897 | 0% | +$154 | |||||
| D | 2019-01-07 | BMRN | Biomarin Pharmaceutical Inc | Bienaime Jean Jacques | CEO | S - Sale+OE | $87.58 | -3,000 | 469,791 | -1% | -$262,740 | |||||
2019-01-08 | FLKS | Flex Pharma, Inc. | Boston Foundation, Inc. | 10% | S - Sale | $0.40 | -263,000 | 1,937,000 | -12% | -$104,306 | ||||||
| DM | 2019-01-07 | UTHR | United Therapeutics Corp | Rothblatt Martine A | COB, CEO | S - Sale+OE | $113.28 | -14,109 | 683,795 | -2% | -$1,598,276 | |||||
2019-01-08 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $3.61 | +35,000 | 212,259,633 | 0% | +$126,376 | ||||||
| DM | 2019-01-04 | ITCI | Intra-Cellular Therapies, Inc. | Mates Sharon | COB, Pres, CEO | S - Sale+OE | $11.58 | -52,202 | 1,138,707 | -4% | -$604,310 | |||||
| DM | 2019-01-04 | ITCI | Intra-Cellular Therapies, Inc. | Halstead Michael | EVP, GC | S - Sale+OE | $11.58 | -24,566 | 191 | -99% | -$284,418 | |||||
| DM | 2019-01-04 | ITCI | Intra-Cellular Therapies, Inc. | Hineline Lawrence J. | SVP of Finance CFO | S - Sale+OE | $11.58 | -24,566 | 15,832 | -61% | -$284,383 | |||||
| DM | 2019-01-04 | ITCI | Intra-Cellular Therapies, Inc. | Vanover Kimberly E. | SVP, Early Stage Clinical Dev. | S - Sale+OE | $11.52 | -10,156 | 27,068 | -27% | -$116,979 | |||||
| D | 2019-01-04 | ITCI | Intra-Cellular Therapies, Inc. | Davis Robert E | SVP, Chief Scientific Officer | S - Sale+OE | $11.46 | -9,564 | 43,989 | -18% | -$109,630 | |||||
| DM | 2019-01-07 | ARNA | Arena Pharmaceuticals Inc | Klassen Preston | EVP, CMO | S - Sale+OE | $42.06 | -19,000 | 0 | -100% | -$799,066 | |||||
| D | 2019-01-04 | FTSV | Forty Seven, Inc. | Takimoto Chris H | Chief Medical Officer | S - Sale+OE | $15.55 | -8,000 | 0 | -100% | -$124,362 | |||||
2019-01-04 | MYOK | Myokardia Inc | Gianakakos Anastasios | Pres, CEO | P - Purchase | $39.86 | +2,500 | 704,810 | 0% | +$99,647 | ||||||
| D | 2019-01-07 | SPPI | Spectrum Pharmaceuticals Inc | Maida Anthony E III | Dir | S - Sale+OE | $10.00 | -7,250 | 32,988 | -18% | -$72,500 | |||||
| M | 2019-01-04 | CERC | Cerecor Inc. | Armistice Capital, LLC | Dir, 10% | P - Purchase | $3.48 | +27,004 | 18,155,803 | 0% | +$93,914 | |||||
2019-01-07 | TCDA | Tricida, Inc. | Otto Dawn Parsell | SVP, Clinical Development | S - Sale | $23.27 | -665 | 0 | -100% | -$15,475 | ||||||
2019-01-07 | IMGN | Immunogen Inc | Gregory Richard J. | EVP, CSO | S - Sale | $5.27 | -3,038 | 236,056 | -1% | -$16,014 | ||||||
2019-01-07 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $3.56 | +55,000 | 212,224,633 | 0% | +$195,922 | ||||||
| M | 2019-01-03 | ARPO | Aerpio Pharmaceuticals, Inc. | Satter Muneer A | Dir, 10% | P - Purchase | $2.12 | +60,000 | 5,558,017 | +1% | +$127,462 | |||||
2019-01-07 | VRCA | Verrica Pharmaceuticals Inc. | Stalfort Sean | Dir | P - Purchase | $10.45 | +9,221 | 430,860 | +2% | +$96,386 | ||||||
2019-01-07 | VRCA | Verrica Pharmaceuticals Inc. | Manning Paul B | Dir, 10% | P - Purchase | $11.18 | +47,500 | 9,622,361 | 0% | +$530,811 | ||||||
| D | 2019-01-07 | IMDZ | Immune Design Corp. | Paya Carlos V | Pres, CEO | S - Sale+OE | $1.58 | -13,014 | 156,576 | -8% | -$20,591 | |||||
| D | 2019-01-07 | OPHT | Ophthotech Corp. | Westby Keith | SVP, COO | S - Sale+OE | $1.30 | -299 | 32,606 | -1% | -$389 | |||||
| D | 2019-01-07 | IMDZ | Immune Design Corp. | Ter Meulen Jan Henrik | Chief Scientific Officer | S - Sale+OE | $1.59 | -3,414 | 83,982 | -4% | -$5,415 | |||||
| D | 2019-01-07 | OPHT | Ophthotech Corp. | Guyer David R | Exec COB | S - Sale+OE | $1.30 | -3,859 | 43,164 | -8% | -$5,017 | |||||
| D | 2019-01-07 | IMDZ | Immune Design Corp. | Yurasov Sergey | SVP, Clinic. Devel., CMO | S - Sale+OE | $1.57 | -3,522 | 78,756 | -4% | -$5,536 | |||||
| D | 2019-01-07 | IMDZ | Immune Design Corp. | Brady Stephen R | EVP, Strategy, Finance | S - Sale+OE | $1.58 | -5,516 | 96,599 | -5% | -$8,722 | |||||
| DM | 2019-01-03 | PAHC | Phibro Animal Health Corp | Bendheim Daniel M | EVP, Corporate Strategy | S - Sale+OE | $31.74 | -7,500 | 0 | -100% | -$238,075 | |||||
| DM | 2019-01-03 | FGEN | Fibrogen Inc | Neff Thomas B | CEO | S - Sale+OE | $44.39 | -60,000 | 5,420,890 | -1% | -$2,663,480 | |||||
| M | 2018-05-02 | AZRX | Azurrx Biopharma, Inc. | Ross Edmund Burke Jr. | 10% | P - Purchase | $1.35 | +139,545 | 2,540,555 | +6% | +$188,472 | |||||
| D | 2019-01-04 | UTHR | United Therapeutics Corp | Rothblatt Martine A | COB, CEO | S - Sale+OE | $111.51 | -7,055 | 683,795 | -1% | -$786,719 | |||||
| M | 2019-01-03 | VRCA | Verrica Pharmaceuticals Inc. | Davidson Matt | 10% | S - Sale | $9.80 | -33,276 | 3,048,693 | -1% | -$326,259 | |||||
| M | 2019-01-03 | KALV | Kalvista Pharmaceuticals, Inc. | Svlsf Iv, LLC | 10% | S - Sale | $20.25 | -4,299 | 70,222 | -6% | -$87,073 | |||||
2019-01-04 | ESPR | Esperion Therapeutics, Inc. | Biotech Target N V | 10% | P - Purchase | $41.29 | +80,000 | 3,472,964 | +2% | +$3,303,256 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |